新一代体外诊断市场－全球产业规模、份额、趋势、机会及预测（按类型、产品、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球新一代体外诊断市场预计将从 2025 年的 927.9 亿美元成长到 2031 年的 1,549.3 亿美元，复合年增长率为 8.92%。

新一代体外诊断（IVD）利用先进的分析评估技术，结合分子、基因组和高通量调查方法，能够以极高的速度和准确性从生物检体中识别疾病。该行业的主要驱动力是日益增长的个人化医疗和疾病早期检测需求，从而实现精准的治疗策略。此外，全球感染疾病和慢性病发病率的不断上升也是一个关键驱动因素，迫使医疗基础设施将这些精准诊断设备纳入标准临床工作流程，以改善患者的治疗效果。

然而，由于监管环境严格且不断变化，对製造商施加了沉重的合规义务，市场成长面临许多障碍。获得核准的高昂成本和复杂流程可能会延缓新技术的发布，并限制创新者进入市场。这种监管负担迫使企业投入大量资源来满足新的标准。根据 MedTech Europe 的一份报告，2024 年的一项调查显示，79% 的体外诊断製造商已对其至少部分产品线进行了修改，以符合体外诊断医疗设备法规 (IVDMR) 的严格要求。

市场驱动因素

感染疾病和慢性病的日益增多是推动全球下一代体外诊断市场发展的主要动力。医疗系统越来越依赖先进的诊断技术来应对癌症等疾病的不断蔓延，这就需要灵敏度更高、出结果更快的设备。疾病发生率的上升促使人们必须采用基因组和分子检测技术，以便更早进行治疗，提高患者的存活率。根据美国癌症协会2024年1月发布的《2024年癌症事实与数据》，预计2024年美国新增癌症病例约为2,001,140例，这凸显了早期识别恶性肿瘤所需的精准诊断工具的紧迫性。

此外，将机器学习和人工智慧融入诊断流程将提高营运效率和分析准确性，从而加速市场扩张。这些技术有助于实现复杂数据分析的自动化，尤其是在数位病理学和基因组学领域，从而减少人为错误并减轻实验室技术人员的负担。截至2024年8月，美国食品药物管理局（FDA）已核准950种采用人工智慧和机器学习医疗设备，显示计算工具在诊断领域的应用正在迅速普及。这种技术整合不仅提高了诊断准确性，还透过提升生产力增强了产业的财务状况。正如生物梅里埃在2024年4月发布的《2024年第一季业务回顾》中所显示，临床诊断解决方案的稳定普及带来了9.8%的有机销售额成长。

市场挑战

严格且不断变化的法规结构是限制全球下一代体外诊断市场发展的主要阻碍因素。製造商必须经历复杂的核准程序，这些程序要求提供大量的临床概念验证和详尽的文檔，导致营运成本显着增加，研发週期延长。这种合规负担迫使企业将大量资源从产品创新和研发转移到满足政府的要求。因此，先进诊断技术的市场推广往往被延迟，减缓了新解决方案的上市速度，并造成了不确定性抑制了对潜在颠覆性技术的投资。

这些监管负担直接影响策略规划和市场部署，有效阻碍了下一代诊断设备在全球的普及。 2024年，《欧洲医疗技术》杂誌报告称，与先前的法规结构相比，主要体外诊断试剂製造商选择欧盟作为其首发市场的比率下降了40%。这一急剧下降表明，日益增多的监管障碍阻碍了企业优先发展关键市场，从而影响了整个行业的成长前景，并限制了人们获得必要的诊断检测。

市场趋势

全球新一代体外诊断市场正经历重大转型，从传统医院实验室以外的快速诊断需求转向照护现场检测（POC​​）和分散式分子检测。这一趋势的特点是小型自动化分子检测设备在药房、急诊中心和诊所的广泛应用，从而为感染疾病提供即时治疗方案。这种结构性变化减少了与中心检查室处理相关的物流延误，并提高了患者在社区环境中获得复杂检测的便利性。丹纳赫公司于2024年10月发布的2024年第三季财报显示，其Cefeed部门仅呼吸道检测一项就创造了4.25亿美元的收入，这充分证明了市场对这些便捷检测方式的持续需求，也体现了患者就近分子检测的显着普及。

同时，用于评估微量残存疾病(MRD) 和非侵入性癌症后续观察的液态生物检体技术正呈现爆炸性成长。医疗专业人员越来越多地使用循环肿瘤 DNA (ctDNA) 分析来监测治疗反应并早期发现復发，从而实现比放射影像学更早识别復发，进而实现更精准的癌症治疗。这种从血液样本进行基因组分析的转变，减少了对侵入性组织切片检查的需求，同时提供了肿瘤进展的即时数据。 2024 年 11 月，Natera 在 2024 年第三季财报中宣布，该季度进行了约 137,100 例肿瘤检测。与去年同期相比，这一数字显着增长了 54.4%，主要得益于该公司个人化液态生物检体解决方案的临床应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球下一代体外诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（核心检查室诊断、即时检验、分子诊断、其他）
  • 依产品分类（耗材、设备、软体）
  • 依应用领域（肿瘤/癌症、感染疾病、糖尿病、心臟病、其他）
  • 依最终使用者（医院/诊所、诊断检查室、学术研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美下一代体外诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲下一代体外诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区下一代体外诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲下一代体外诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲下一代体外诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球下一代体外诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Becton, Dickinson, and Company
• Qiagen GmbH
• Illumina Inc.
• Beckman Coulter, Inc.
• Invivoscribe, Inc.
• Sysmex Corporation
• bioMerieux SA
• VWR International, LLC.
• Danaher Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Next-Generation In-vitro Diagnostics Market is projected to expand from a valuation of USD 92.79 Billion in 2025 to USD 154.93 Billion by 2031, reflecting a CAGR of 8.92%. Next-Generation In-vitro Diagnostics (IVD) involve sophisticated analytical assessments on biological specimens, leveraging molecular, genomic, and high-throughput methodologies to identify diseases with superior speed and accuracy. The industry is principally driven by the escalating need for personalized medicine and early disease identification, which facilitates specific therapeutic strategies. Additionally, the growing worldwide incidence of infectious diseases and chronic conditions acts as a vital accelerator, forcing healthcare infrastructures to incorporate these precise diagnostic instruments into standard clinical workflows to enhance patient results.

Nevertheless, market growth faces substantial hurdles due to a rigid and shifting regulatory landscape that imposes heavy compliance obligations on manufacturers. The substantial expense and intricacy involved in securing approvals can postpone the release of new technologies and restrict market entry for innovators. This regulatory strain compels firms to allocate considerable assets toward meeting emerging standards. As reported by MedTech Europe, a 2024 survey revealed that 79% of IVD producers had shifted at least a portion of their product lines to align with the stringent In Vitro Diagnostic Medical Devices Regulation.

Market Driver

The escalating prevalence of infectious and chronic diseases serves as a major impetus for the Global Next-Generation In-vitro Diagnostics Market. Healthcare frameworks increasingly depend on sophisticated diagnostic techniques to handle the rising load of conditions like cancer, requiring instruments that provide superior sensitivity and rapid results. This increase in disease occurrence mandates the implementation of genomic and molecular testing to enable early treatment and enhance patient survival. Data from the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, estimated roughly 2,001,140 new cancer diagnoses in the United States for the year, highlighting the urgent requirement for accurate diagnostic tools to identify malignancies in their initial phases.

Furthermore, incorporating machine learning and artificial intelligence into diagnostic processes hastens market expansion by improving operational efficiency and analytical accuracy. These technologies facilitate the automation of intricate data analysis, especially within digital pathology and genomics, which diminishes human error and reduces the burden on laboratory staff. By August 2024, the U.S. Food and Drug Administration had authorized 950 medical devices enabled by artificial intelligence and machine learning, indicating the swift adoption of computational tools in diagnostics. This technological convergence not only sharpens diagnostic precision but also bolsters the sector's financial health through heightened productivity, as evidenced by bioMerieux's April 2024 'First-Quarter 2024 Business Review', which reported a 9.8% organic sales increase driven by the steady uptake of clinical diagnostic solutions.

Market Challenge

A rigid and changing regulatory framework acts as a notable constraint on the Global Next-Generation In-vitro Diagnostics Market. Manufacturers must move through intricate approval procedures that demand extensive clinical proof and thorough documentation, resulting in considerably higher operational expenses and longer development cycles. This weight of compliance obliges companies to divert essential resources away from product innovation and development to satisfy administrative prerequisites. As a result, the market introduction of sophisticated diagnostic technologies is frequently postponed, slowing the rate at which novel solutions become available and creating uncertainty that discourages investment in potentially revolutionary innovations.

Such regulatory strain directly influences strategic planning and market reach, effectively hindering the worldwide spread of next-generation diagnostic instruments. In 2024, MedTech Europe reported that the percentage of major IVD manufacturers selecting the European Union as their initial launch region fell by 40% compared to earlier regulatory frameworks. This precipitous drop illustrates how intensified regulatory hurdles dissuade firms from prioritizing key markets, thereby impeding the industry's overall growth prospects and restricting access to essential diagnostic tests.

Market Trends

The Global Next-Generation In-vitro Diagnostics Market is experiencing a major transition toward point-of-care and decentralized molecular testing, fueled by the need for quick diagnostic results outside of conventional hospital labs. This movement is defined by the extensive implementation of small, automated molecular units in pharmacies, urgent care facilities, and clinics, enabling immediate therapeutic choices for infectious diseases. This structural shift lessens logistical lags linked to central lab processing and enhances patient access to complex testing in local environments. Highlighting the ongoing need for these accessible options, Danaher Corporation's 'Third Quarter 2024 Earnings Results' from October 2024 noted that its Cepheid division produced $425 million in revenue from respiratory testing alone, indicating a substantial volume of near-patient molecular tests.

Simultaneously, there is a surge in the utilization of liquid biopsy technologies for minimal residual disease (MRD) assessment and non-invasive cancer tracking. Medical professionals are increasingly employing circulating tumor DNA (ctDNA) analysis to monitor treatment efficacy and identify recurrence much sooner than radiological imaging, thus allowing for more exact oncological care. This shift toward genomic profiling via blood samples reduces the necessity for invasive tissue biopsies while offering real-time data on tumor progression. In November 2024, Natera, Inc. reported in its 'Third Quarter 2024 Financial Results' that it conducted roughly 137,100 oncology tests during the quarter, marking a significant 54.4% rise from the previous year, largely fueled by the clinical adoption of its personalized liquid biopsy offerings.

Key Market Players

• Thermo Fisher Scientific Inc.
• Becton, Dickinson, and Company
• Qiagen GmbH
• Illumina Inc.
• Beckman Coulter, Inc.
• Invivoscribe, Inc.
• Sysmex Corporation
• bioMerieux SA
• VWR International, LLC.
• Danaher Corporation

Report Scope

In this report, the Global Next-Generation In-vitro Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation In-vitro Diagnostics Market, By Type

• Core Laboratory Diagnostics
• PoC Testing
• Molecular Diagnostics
• Others

Next-Generation In-vitro Diagnostics Market, By Product

• Consumables
• Instruments
• Software

Next-Generation In-vitro Diagnostics Market, By Application

• Oncology/Cancer
• Infectious Diseases
• Diabetes
• Cardiology
• Others

Next-Generation In-vitro Diagnostics Market, By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Academic and Research Institutions
• Others

Next-Generation In-vitro Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation In-vitro Diagnostics Market.

Available Customizations:

Global Next-Generation In-vitro Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation In-vitro Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Core Laboratory Diagnostics, PoC Testing, Molecular Diagnostics, Others)
  • 5.2.2. By Product (Consumables, Instruments, Software)
  • 5.2.3. By Application (Oncology/Cancer, Infectious Diseases, Diabetes, Cardiology, Others)
  • 5.2.4. By End User (Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutions, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Next-Generation In-vitro Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Next-Generation In-vitro Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Next-Generation In-vitro Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Next-Generation In-vitro Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Next-Generation In-vitro Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Next-Generation In-vitro Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Next-Generation In-vitro Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Next-Generation In-vitro Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Next-Generation In-vitro Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Next-Generation In-vitro Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Next-Generation In-vitro Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Next-Generation In-vitro Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Next-Generation In-vitro Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Next-Generation In-vitro Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Next-Generation In-vitro Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Next-Generation In-vitro Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Next-Generation In-vitro Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Next-Generation In-vitro Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Next-Generation In-vitro Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Next-Generation In-vitro Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Next-Generation In-vitro Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Next-Generation In-vitro Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Next-Generation In-vitro Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Next-Generation In-vitro Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Next-Generation In-vitro Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Becton, Dickinson, and Company
• 15.3. Qiagen GmbH
• 15.4. Illumina Inc.
• 15.5. Beckman Coulter, Inc.
• 15.6. Invivoscribe, Inc.
• 15.7. Sysmex Corporation
• 15.8. bioMerieux SA
• 15.9. VWR International, LLC.
• 15.10. Danaher Corporation

16. Strategic Recommendations

17. About Us & Disclaimer